scholarly journals Hemodynamic Effects of the Oral Prostacyclin (IP) Receptor Agonist Ralinepag in Pulmonary Arterial Hypertension

CHEST Journal ◽  
2017 ◽  
Vol 152 (4) ◽  
pp. A738
Author(s):  
Fernando Torres ◽  
Harrison Farber ◽  
Arsen Ristić ◽  
Vallerie McLaughlin ◽  
John Adams ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Hemodynamic Effects ◽  
Ip Receptor ◽  
Pulmonary Arterial

Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension

2019 ◽  
Vol 29 (06) ◽  
pp. 849-851 ◽  
Author(s):  
Rachel Koo ◽  
Jennifer Lo ◽  
Matthew J. Bock
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Adverse Effects ◽  
Arterial Hypertension ◽  
Receptor Agonist ◽  
Ip Receptor ◽  
Pulmonary Arterial

AbstractSelexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.

scholarly journals Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

2018 ◽  
Vol 8 (3) ◽  
pp. 204589401879358 ◽  
Author(s):  
Martin Koestenberger ◽  
Georg Hansmann
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Children And Adolescents ◽  
Receptor Agonist ◽  
Off Label ◽  
Ip Receptor ◽  
Targeted Agent ◽  
Pulmonary Arterial ◽  
Prostacyclin Analog

We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy.

Sign in / Sign up

Export Citation Format

Share Document